Related Experiment Video
Updated: Jul 26, 2025

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
METTL14 is decreased and regulates m6 A modification of α-synuclein in Parkinson's disease
Honghu He1, Qinxin Zhang1, Jiajia Liao1,2
1Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Abstract:
N6-methyladenosine (m6A), an emerging modification of messenger RNA, has been implicated in many biological processes. However, its role in Parkinson's disease (PD) remains largely unknown. Here, we investigated the role of m6A modification and its underlying mechanism in PD. First, 86 individuals with PD and 86 healthy controls were recruited from a pilot multicenter cohort. Levels of m6A and its modulators in peripheral blood mononuclear cells of patients with PD and controls were measured using an m6A RNA methylation quantification kit and quantitative real-time PCR. The underlying mechanism of m6A modification in PD was investigated in vitro through RNA immunoprecipitation assay, RNA stability assay, gene silencing or overexpression, western blot, and confocal immunoassay. The results show that mRNA levels of m6A, METTL3, METTL14, and YTHDF2 in patients with PD were significantly lower than in healthy controls, and METTL14 was the main factor involved in abnormal m6A modification. Area under the curve (AUC) analysis suggests METTL14 may provide excellent diagnostic capability for PD, especially when combined with plasma α-synuclein (α-syn). Spearman correlation analysis identified that METTL14 was moderately negatively correlated with plasma α-syn and the motor function of PD. Mechanistic experiments demonstrated that Mettl14 targets and regulates the expression of the α-syn gene using its methylation function. Overexpression of Mettl14 dramatically increased m6 A modification of α-syn mRNA and weakened its stability. Further results suggest that α-syn mRNA was modified by Mettl14 binding of an m6 A motif in the coding region of α-syn mRNA, while the reading protein Ythdf2 was involved in recognizing m6 A-modified α-syn mRNA. Taken together, our results reveal the potential of METTL14 as a novel diagnostic biomarker for PD and identify modification of pathogenic α-syn protein by METTL14 via an m6 A-YTHDF2-dependent mechanism.
Insights
N6-methyladenosine (m6A) levels are lower in Parkinson's disease (PD) patients. METTL14, a key m6A regulator, shows potential as a diagnostic biomarker for PD by targeting alpha-synuclein mRNA.
Area of Science:
- Epigenetics and RNA modifications
- Neurodegenerative diseases
- Molecular mechanisms of disease
Background:
- N6-methyladenosine (m6A) is a prevalent mRNA modification involved in various biological processes.
- The role of m6A modification in Parkinson's disease (PD) pathogenesis is not well understood.
- Investigating m6A's role could reveal novel insights into PD mechanisms and potential therapeutic targets.
Purpose of the Study:
- To investigate the role and underlying mechanisms of m6A modification in Parkinson's disease.
- To assess the diagnostic potential of m6A regulators as biomarkers for PD.
- To elucidate the specific molecular pathway involving m6A in PD pathogenesis.
Main Methods:
- Recruitment of 86 PD patients and 86 healthy controls for a pilot multicenter cohort study.
- Quantification of m6A levels and modulators (METTL3, METTL14, YTHDF2) in peripheral blood mononuclear cells.
- In vitro mechanistic studies including RNA immunoprecipitation, stability assays, gene manipulation, and western blotting.
Main Results:
- Significantly lower mRNA levels of m6A, METTL3, METTL14, and YTHDF2 were observed in PD patients compared to controls.
- METTL14 was identified as the primary factor in abnormal m6A modification and demonstrated diagnostic capability for PD, especially with alpha-synuclein.
- METTL14 targets and downregulates alpha-synuclein (α-syn) expression by increasing m6A modification and decreasing the stability of α-syn mRNA.
Conclusions:
- METTL14 is a key regulator of m6A modification in Parkinson's disease.
- METTL14 shows promise as a novel diagnostic biomarker for PD, potentially in combination with plasma α-synuclein.
- METTL14-mediated m6A modification of α-syn mRNA, recognized by YTHDF2, represents a crucial mechanism in PD pathogenesis.
More Related Videos
08:33Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models
Published on: March 24, 2019
06:07Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
Published on: June 23, 2023
Related Concept Videos
Neural Regulation
Parkinson's Disease: Overview